Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS 3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS 4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 5	AUG 24	CA/CAplus enhanced with legal status information for U.S. patents
NEWS 6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS 7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS 8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS 9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS 10	NOV 23	Addition of SCAN format to selected STN databases
NEWS 11	NOV 23	Annual Reload of IFI Databases
NEWS 12	DEC 01	FRFULL Content and Search Enhancements
NEWS 13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS 14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS 15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS 16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information
NEWS 17	DEC 21	New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAplus
NEWS 18	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS 19	JAN 25	Annual Reload of MEDLINE database
NEWS 20	FEB 16	STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS 21	FEB 16	Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS 22	FEB 16	New FASTA Display Formats Added to USGENE and PCTGEN
NEWS 23	FEB 16	INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS 24	FEB 16	INSPEC Adding Its Own IPC codes and Author's E-mail Addresses

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

```
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:41:35 ON 16 MAR 2010

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 12:42:15 ON 16 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 MAR 2010  HIGHEST RN 1210111-73-1
DICTIONARY FILE UPDATES:  15 MAR 2010  HIGHEST RN 1210111-73-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10781894_NEW_20100316.str
```



chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 21 22
chain bonds :
1-2 1-5 2-3 3-4 3-17 5-6 5-7 6-21 7-8 8-9 9-10 10-11 11-12 12-13
13-14 13-15 13-16 17-18 21-22
exact/norm bonds :
2-3 3-4 5-6 7-8 8-9 9-10
exact bonds :
1-2 1-5 3-17 5-7 6-21 10-11 11-12 12-13 13-14 13-15 13-16 17-18 21-22

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 21:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss
SAMPLE SEARCH INITIATED 12:42:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        8 TO ITERATE

100.0% PROCESSED        8 ITERATIONS                                4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            8 TO      329
PROJECTED ANSWERS:               4 TO      200

L2            4 SEA SSS SAM L1

=> d l2 1-4

L2   ANSWER 1 OF 4  REGISTRY  COPYRIGHT 2010 ACS on STN
RN   210418-12-5  REGISTRY
ED   Entered STN:  26 Aug 1998
CN   3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium,
     4-hydroxy-7-methoxy-N,N,N-trimethyl-10-oxo-, chloride, 4-oxide (9CI)  (CA
     INDEX NAME)
MF   C27 H58 N2 O6 P . Cl
SR   CAS Client Services
CRN  (742681-49-8)
```



L2 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2010 ACS on STN
RN 207298-97-3 REGISTRY
ED Entered STN: 17 Jun 1998
CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium,
4-hydroxy-N,N,N-trimethyl-7-(octyloxy)-10-oxo-, inner salt, 4-oxide (9CI)
(CA INDEX NAME)
MF C26 H55 N2 O6 P
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2010 ACS on STN
RN 207298-94-0 REGISTRY
ED Entered STN: 17 Jun 1998
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium,
7-(hexyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI)
(CA INDEX NAME)
MF C26 H55 N2 O6 P
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2010 ACS on STN
RN 207298-93-9 REGISTRY
ED Entered STN: 17 Jun 1998

CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium,
    4-hydroxy-N,N,N-trimethyl-7-(octyloxy)-10-oxo-, inner salt, 4-oxide (9CI)
    (CA INDEX NAME)
MF C28 H59 N2 O6 P
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d his

    (FILE 'HOME' ENTERED AT 12:41:35 ON 16 MAR 2010)

    FILE 'REGISTRY' ENTERED AT 12:42:15 ON 16 MAR 2010
L1   STRUCTURE UPLOADED
L2   4 S L1 SSS

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 191.05 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 12:42:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   96 TO ITERATE

100.0% PROCESSED   96 ITERATIONS   47 ANSWERS
SEARCH TIME: 00.00.02

L3   47 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                       ENTRY   SESSION
FULL ESTIMATED COST   199.94   200.16

FILE 'CAPLUS' ENTERED AT 12:43:06 ON 16 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 16 Mar 2010 VOL 152 ISS 12

FILE LAST UPDATED: 15 Mar 2010 (20100315/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4   23 L3

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5   23 DUP REM L4 (0 DUPLICATES REMOVED)

=> s l5 and (virus or viral)
L6   23 S L5
        434512 VIRUS
         91338 VIRUSES
        451209 VIRUS
                  (VIRUS OR VIRUSES)
        218316 VIRAL
            29 VIRALS
        218333 VIRAL
                  (VIRAL OR VIRALS)
L7   10 L6 AND (VIRUS OR VIRAL)

=> d l7 1-10 ibib abs hitstr

L7   ANSWER 1 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:198407 CAPLUS
DOCUMENT NUMBER: 144:403777
TITLE: Using small molecules to overcome drug resistance induced by a viral oncogene
AUTHOR(S):   Smukste, Inese; Bhalala, Oneil; Persico, Marco; Stockwell, Brent R.
CORPORATE SOURCE: Department of Biological Sciences and Department of Chemistry, Fairchild Center, Columbia University, New York, NY, 10027, USA
SOURCE: Cancer Cell (2006), 9(2), 133-146
                         CODEN: CCAECI; ISSN: 1535-6108
PUBLISHER: Cell Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB   We used small mol. screening to discover compds. and mechanisms for overcoming E6 oncogene-mediated drug resistance. Using high-throughput screening in isogenic cell lines, we identified compds. that potentiate doxorubicin's lethality in E6-expressing colon cancer cells. Such compds. included quaternary ammonium salts, protein synthesis inhibitors, 11-deoxyprostaglandins, and two addnl. classes of compds.-analogs of 1,3-bis(4-morpholinylmethyl)-2-imidazolidinethione (a thiourea) and acylated secondary amines that we named indoxins. Indoxins upregulated topoisomerase IIα, the target of doxorubicin, thereby increasing doxorubicin lethality. We developed a photolabeling strategy to identify targets of indoxin and discovered a nuclear actin-related protein complex as a candidate indoxin target.

IT 88876-07-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(small mols. which overcome drug resistance induced by a viral oncogene)
RN 88876-07-7 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:904330 CAPLUS
DOCUMENT NUMBER: 143:222464
TITLE: Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
INVENTOR(S): Fleming, Ronald A.; Hes, Jan V.; Huang, Yunsheng; Read, Russ H.; Morris-Natschke, Susan L.; Ishaq, Khalid S.; Kucera, Louis S.; Furman, Phillip A.
PATENT ASSIGNEE(S): Kucera Pharmaceutical Company, USA
SOURCE: U.S. Pat. Appl. Publ., 36 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050187192	A1	20050825	US 2004-783927	20040220
PRIORITY APPLN. INFO.:			US 2004-783927	20040220

OTHER SOURCE(S): MARPAT 143:222464
AB Provided are compds., methods and pharmaceutical compns. for treating a host, especially a human, infected with a togavirus, herpes virus and/or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-coronavirus phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and/or alternation with one or more other antiviral agents. The EC50 of an alkylamido-2-alkoxypropylphosphocholine against varicella zoster virus was 0.48 μg/mL.
IT 252371-27-0 443882-90-4 443882-91-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phospholipids for treatment of infection by togaviruses, herpes viruses and coronaviruses)

RN 252371-27-0 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium, 7-(decyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 443882-90-4 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 443882-91-5 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L7 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:902611 CAPLUS
DOCUMENT NUMBER: 143:241938
TITLE: Methods and compositions for the treatment of respiratory syncytial virus
INVENTOR(S): Kucera, Louis S.; Morris-Natschke, Susan L.; Ishaq, Khalid S.; Fleming, Ronald A.; Hess, Jan V.; Huang, Yunsheng; Read, Russ H.; Furman, Phillip A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 29 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 20050187191 A1 20050825 US 2004-781894 20040220
WO 2005099719 A2 20051027 WO 2005-US3972 20050209
WO 2005099719 A3 20070322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-781894 A 20040220
OTHER SOURCE(S): MARPAT 143:241938

AB The invention includes compds. useful for inhibiting RSV replication and treating a host infected with RSV. The invention also includes methods of treating a host infected with RSV by administering to the host an anti-RSV effective amount of a compound of the invention.

IT 443882-90-4, KPC 11 443882-91-5, KPC 15
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for treatment of respiratory syncytial virus)

RN 443882-90-4 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 443882-91-5 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



IT 207298-91-7 207298-93-9 252371-27-0
443882-96-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for treatment of respiratory syncytial virus)

RN 207298-91-7 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-(dodecyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 207298-93-9 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-7-(octyloxy)-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 252371-27-0 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium, 7-(decyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 443882-96-0 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-butoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



L7 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1998:435743 CAPLUS
DOCUMENT NUMBER: 129:90448
ORIGINAL REFERENCE NO.: 129:18491a,18494a
TITLE: Method of treating hepatitis virus infections
INVENTOR(S): Kucera, Louis S.; Morris-Natschke, Susan L.
PATENT ASSIGNEE(S): Wake Forest University, USA; University of North

Carolina
SOURCE: U.S., 17 pp., Cont.-in-part of U. S. Ser. No. 74,943, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5770584	A	19980623	US 1995-465947	19950606
US 6030960	A	20000229	US 1998-102308	19980622

PRIORITY APPLN. INFO.: US 1993-74943 B2 19930610
US 1995-465947 A3 19950606
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 129:90448

AB A method of treating hepatitis virus infection is disclosed. The method involves administering to a human subject in need of such treatment an effective hepatitis virus-combating amount of an alkyl lipid or alkyl lipid derivative

IT 112989-01-2P 112989-02-3P 209532-02-5P
209532-03-6P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(alkyl lipids for treating hepatitis virus infections)

RN 112989-01-2 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphapentacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



RN 112989-02-3 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



RN 209532-02-5 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 209532-03-6 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphapentacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1998:205430 CAPLUS
DOCUMENT NUMBER: 128:316940
ORIGINAL REFERENCE NO.: 128:62637a,62640a
TITLE: In vitro evaluation and characterization of newly designed alkylamidophospholipid analogs as anti-human immunodeficiency virus type 1 agents
AUTHOR(S): Kucera, L. S.; Iyer, N.; Morris-Natschke, S. L.; Chen, S. Y.; Gumus, F.; Ishaq, K.; Herrmann, D. B. J.
CORPORATE SOURCE: Wake Forest University School Medicine, Winston-Salem, NC, USA
SOURCE: Antiviral Chemistry & Chemotherapy (1998), 9(2), 157-165
CODEN: ACCHEH; ISSN: 0956-3202
PUBLISHER: International Medical Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Our labs. first reported two novel classes of complex synthetic lipids, including alkylamidophosphocholines (PC lipid; CP-51) and alkylamidophosphate ester-linked lipid-AZT conjugates (lipid-AZT conjugates; CP-92), with selective and potent activity against human immunodeficiency virus type 1 (HIV-1). To extend these observations, we synthesized addnl. PC lipids and lipid-AZT conjugates (INK and INK-AZT conjugate) to evaluate their structure-activity relationships by testing for selectivity against infectious wild-type (wt) and drug-resistant HIV-1 replication, virus fusogenic activity and toxicity replication, virus fusogenic activity and toxicity for mouse bone marrow cells. PC lipid compds. with medium chain lengths at positions 1 and 2 gave an improved selective index (SI). INK-3, with 12 and 8 carbons and INK-15, with 10 and 12 carbons were among the most selective when evaluated in CEM-SS cells. INK-14, a lipid-AZT conjugate where AZT replaced the choline in PC lipid INK-3, gave the highest SI of >1250 against both infectious wt HIV-1 replication in CEM-SS cells and a

clin. isolate in peripheral blood leukocytes. Notably, the PC lipid compds. INK-3 and INK-15, but not the lipid-AZT conjugate INK-14, were potent inhibitors of matched pairs of AZT-sensitive and AZT-resistant HIV-1 clin. isolates. INK-3 also inhibited replication of HIV-2 and TIBO-resistant HIV-1, and inhibited HIV-1-mediated fusogenic activity by 78, 41 and 9% in a dose-dependent manner. The TC50 for mouse bone marrow cells was >100 μg/mL for CP-51 and 0.142-0.259 μg/mL for AZT. These data suggest that optimum PC lipid compds. are significantly less toxic than AZT and have high potential as novel therapeutic agents for AIDS.

IT 207298-91-7P 207298-92-8P 207298-93-9P
207298-94-0P 207298-95-1P 207298-97-3P
207298-99-5P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anti-HIV-1 activity and preparation of alkylamidophospholipid analogs)

RN 207298-91-7 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-(dodecyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 207298-92-8 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-(decyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 207298-93-9 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-7-(octyloxy)-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 207298-94-0 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-(hexyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 207298-95-1 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-7-(octyloxy)-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 207298-97-3 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium, 4-hydroxy-N,N,N-trimethyl-7-(octyloxy)-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 207298-99-5 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium, 7-(dodecyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



IT 112989-02-3, CP 51
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or

effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-HIV-1 activity and preparation of alkylamidophospholipid analogs)

RN 112989-02-3 CAPLUS

CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1995:701769 CAPLUS

DOCUMENT NUMBER: 123:112632

ORIGINAL REFERENCE NO.: 123:20141a,20144a

TITLE: Phospholipids for combating hepatitis B virus infection

INVENTOR(S): Kucera, Louis S.; Morris-Natschke, Susan L.

PATENT ASSIGNEE(S): Wake Forest University, USA; University of North Carolina

SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9428908	A2	19941222	WO 1994-US5855	19940525
WO 9428908	A3	19950323		
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2164717	A1	19941222	CA 1994-2164717	19940525
CA 2164717	C	20091020		
AU 9470448	A	19950103	AU 1994-70448	19940525
EP 702556	A1	19960327	EP 1994-919231	19940525
EP 702556	B1	20021023		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 226437	T	20021115	AT 1994-919231	19940525

PRIORITY APPLN. INFO.: US 1993-74943 A 19930610
WO 1994-US5855 W 19940525

OTHER SOURCE(S): MARPAT 123:112632

GI



I

AB A method of treating infection with hepatitis B virus is disclosed. The method comprises administration of alkyl ether phospholipids and derivs. of formula DCH2XCH2YR1 [Y = S, O, NH, NMe, NHCO, NMeCO; R1 = (un)branched (un)saturated C10-20 alk(en/yn)yl; X = bond, CH2 (un)substituted by OH, alkyl, alkoxy, or alkylthio; D = (PO4)-E, N+R5R6FW Z-; E = (mono/di/trialkyl)ammonioalkyl or a nucleic acid base conjugate; F = alkylene; R5, R6 = H, alkyl; W = OH, SH; Z- = anion]. Several compds. were prepared For example, etherification of isopropylideneglycerol with 1-bromododecane using KOH in PhMe and acid hydrolysis with HCl in MeOH-Et2O mixture gave 71% 3-dodecyloxy-1,2-propanediol. This underwent 1-O-tritylation with Ph3CCl in pyridine, 2-O-alkylation by 1-bromodecane and NaH in THF (51%), and detritylation by p-MeC6H4SO3H in CHCl3-MeOH (63%) to give 3-dodecyloxy-2-decyloxy-1-propanol. The latter underwent esterification with (PhO)2P(O)Cl (60%), hydrogenolysis of the Ph ester to the phosphatidic acid, and reesterification with AZT using DCC (22%) to give title compound (Na salt) I. Another compound, (±)-3-octadecanamido-2-ethoxypropyl-1-phosphocholine, inhibited HBV virion DNA and intracellular RI HBV DNA in expts. to a comparable or greater extent than the standard agent ddC.

IT 112989-01-2P 112989-02-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phospholipids for combating hepatitis B virus)

RN 112989-01-2 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphapentacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



RN 112989-02-3 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1995:694404 CAPLUS
DOCUMENT NUMBER: 123:160151
ORIGINAL REFERENCE NO.: 123:28207a,28210a
TITLE: Membrane-interactive phospholipids inhibit HIV type 1-induced cell fusion and surface gp160/ gp120 binding to monoclonal antibody
AUTHOR(S): Krugner-Higby, Lisa; Goff, David; Edwards, Terri; Iyer, Nathan; Neufeld, Jay; Kute, Timothy; Morris-Natschke, Susan; Ishaq, Khalid; Piantadosi, Claude; Kucera, Louis S.
CORPORATE SOURCE: Wake Forest University, Winsto-Salem, NC, 27157-1064, USA
SOURCE: AIDS Research and Human Retroviruses (1995), 11(6), 705-12
CODEN: ARHRE7; ISSN: 0889-2229
PUBLISHER: Liebert
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Membrane-interactive phospholipids (PLs), previously evaluated for activity against HIV-1 in vitro, are known to affect late steps in viral replication. Studies were done to determine the effects of PL analogs on post-translational processing of HIV-1 proteins, binding of viral surface gp160/gp120 to CD4 receptor, and HIV-1-induced cell fusion. Results of this investigation indicated that PL alone (1-octadecanamido-2-ethoxypropyl-rac-3-phosphocholine, CP-51) and PL-AZT conjugate (1-octadecanamido-2-ethoxypropyl-rac-3-phospho-3'-azido-3'-deoxythymidine, CP-92) have no effect on HIV-1-induced syntheses or processing of gp160/gp120, pr51, p24, or p17 (including myristoylation) in infected cells. Progeny HIV-1 particles made in CP-92-treated H9IIIB cells contained gp120, pr51, and p24; however, these virus particles had reduced capacity to bind to CD4+ cells. Both CP-51 and CP-92 inhibited syncytium (cell fusion) formation between treated HIV-1-infected cells and uninfected CD4+ cells, and, they reduced HIV-1 gp160/gp120 binding to CD4+ cells and monoclonal antibody. These results suggest that anti-HIV-1 activity of PL compds. involves alteration of cell surface membranes and viral envelopes. Phospholipid compds. are a novel class of membrane interactive compds. with potential use in blocking the spread of HIV-1 infection and pathogenesis in AIDS.
IT 112989-02-3, CP 51
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(membrane-interactive phospholipids inhibit HIV type 1-induced cell fusion and surface gp160/ gp120 binding to monoclonal antibody)
RN 112989-02-3 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX

NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)

L7 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1991:185901 CAPLUS
DOCUMENT NUMBER: 114:185901
ORIGINAL REFERENCE NO.: 114:31415a,31418a
TITLE: Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity
AUTHOR(S): Piantadosi, Claude; Marasco, Canio J., Jr.; Morris-Natschke, Susan L.; Meyer, Karen L.; Gumus, Fatma; Surles, Jefferson R.; Ishaq, Khalid S.; Kucera, Louis S.; Iyer, Nathan; et al.
CORPORATE SOURCE: Sch. Pharm., Univ. North Carolina, Chapel Hill, NC, 27599, USA
SOURCE: Journal of Medicinal Chemistry (1991), 34(4), 1408-14
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:185901
GI



I

AB Combinations of an amidoalkylphosphocholine, C17H35CONHCH2CH(OEt)CH2OP(O)(O-)OCH2CH2N+Me3, and AZT were found to cause an apparent synergistic action in suppressing infectious HIV-1 replication. In addition, alkylamido, alkyloxy, and alkylthio ether lipids were chemical linked to anti-HIV-1 nucleosides (AZT and DDI) through phosphate and phosphonate linkages. These conjugates show promising in vitro anti-HIV-1 activity. Also, the conjugates have a 5-10-fold reduction in cell cytotoxicity compared to AZT alone. The most active compound, an alkylamido ether lipid-AZT conjugate, I was found to have a differential selectivity of 1793 in a syncytial plaque assay. In comparison, AZT alone

has a value of 1281.

IT 112989-02-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(anti-HIV-1 activity of)

RN 112989-02-3 CAPLUS

CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



OS.CITING REF COUNT: 36 THERE ARE 36 CAPLUS RECORDS THAT CITE THIS RECORD (37 CITINGS)

L7 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1991:185881 CAPLUS

DOCUMENT NUMBER: 114:185881

ORIGINAL REFERENCE NO.: 114:31411a,31414a

TITLE: In vitro evaluation of phosphocholine and quaternary ammonium containing lipids as novel anti-HIV agents

AUTHOR(S): Meyer, Karen L.; Marasco, Canino J., Jr.; Morris-Natschke, Susan L.; Ishaq, Khalid S.; Piantadosi, Claude; Kucera, Louis S.

CORPORATE SOURCE: Sch. Pharm., Univ. North Carolina, Chapel Hill, NC, 27599, USA

SOURCE: Journal of Medicinal Chemistry (1991), 34(4), 1377-83
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 114:185881

GI



I

AB A series of synthetic lipids containing a two- or three-carbon backbone substituted with a thio, oxy, or amidoalkyl functionality and either a phosphocholine or quaternary ammonium moiety were evaluated as potential anti-HIV-1 agents. Several analogs were identified as possessing activity with the most promising compound being rac-3-octadecanamido-2-ethoxypropylphosphocholine (I). I exhibited an IC50 for the inhibition of plaque formation of 0.16 μM which was 84-fold lower than the IC50 value determined for CEM-SS cell growth inhibition. Initial mechanistic studies have indicated that these compds., unlike AZT, are not reverse transcriptase (RT) inhibitors, but instead appear to inhibit a late step in HIV replication involving virus assembly and infectious virus production Since these lipids are acting via a different, mechanism they represent an alternative approach to the

chemotherapeutic treatment of AIDS as well as candidates for combination therapy with AZT.

IT 88876-07-7 112989-00-1 112989-01-2
112989-02-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(anti-HIV-1 activity of)

RN 88876-07-7 CAPLUS

CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



RN 112989-00-1 CAPLUS

CN 3,5-Dioxa-9-aza-4-phosphapentacosan-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 112989-01-2 CAPLUS

CN 3,5-Dioxa-9-aza-4-phosphapentacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



RN 112989-02-3 CAPLUS

CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



IT 149576-20-5P
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and anti-HIV-1 activity of)
RN 149576-20-5 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphanonacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1990:470710 CAPLUS
DOCUMENT NUMBER: 113:70710
ORIGINAL REFERENCE NO.: 113:11741a,11744a
TITLE: Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation
AUTHOR(S): Kucera, Louis S.; Iyer, Nathan; Leake, Eva; Raben, Adam; Modest, Edward J.; Daniel, Larry W.; Piantadosi, Claude
CORPORATE SOURCE: Bowman Gray Sch. Med., Wake Forest Univ., Winston-Salem, NC, 27103, USA
SOURCE: AIDS Research and Human Retroviruses (1990), 6(4), 491-501
CODEN: ARHRE7; ISSN: 0889-2229
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A new class of membrane-active ether lipid (EL) analogs of platelet-activating factor were studied for in vitro anti-HIV-1 activity. Human T-cell (CEM-ss) monolayers or suspension cultures were used to determine effects of structural modifications of Type A phosphorus-containing and Type B nonphosphorus EL analogs on (a) the inhibitory concn.50 (IC50) for HIV-1 syncytial plaque formation and cell growth, and, (b) virus budding at the cell plasma membrane. Results indicate that representative Type A and Type B EL inhibit HIV-1 but not herpes simplex virus type 2 plaque formation when added before or up to 2 days after viral infection. Anti-HIV-1 activity does not involve direct inactivation of virus infectivity. Type A EL (IC50 range = 0.2-1.4 μM) with alkoxy, alkylthio, or alkyamido substitution at glycerol position 1 and ethoxy or methoxy substitution at position 2, and Type B compds. (IC50 range = 0.33-0.63 μM) with an inverse choline or nitrogen heterocyclic substitution at position 3 have selective activity against HIV-1-infected T-cells. EL treatment of HIV-1-infected cells is associated with subsequent release of reverse transcriptase activity, but infectious virus production is inhibited with time after infection. Electron microscopic examination of HIV-1-infected and EL-treated cells revealed absence of detectable budding virus at the plasma membrane but presence of intracytoplasmic vacuolar virus particles. EL analogs are a novel class of agents that induce defective intracytoplasmic vacuolar HIV-1 formation in T-cells. Being membrane interactive, EL are ideally suited for combination chemotherapy with DNA-interactive anti-HIV nucleoside analogs.
IT 112989-02-3
RL: BIOL (Biological study)
(human immunodeficiency virus infection response to)

RN 112989-02-3 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



OS.CITING REF COUNT: 31 THERE ARE 31 CAPLUS RECORDS THAT CITE THIS RECORD (32 CITINGS)

=> d his

(FILE 'HOME' ENTERED AT 12:41:35 ON 16 MAR 2010)

FILE 'REGISTRY' ENTERED AT 12:42:15 ON 16 MAR 2010
L1 STRUCTURE UPLOADED
L2 4 S L1 SSS
L3 47 S L1 FULL

FILE 'CAPLUS' ENTERED AT 12:43:06 ON 16 MAR 2010
L4 23 S L3
L5 23 DUP REM L4 (0 DUPLICATES REMOVED)
L6 23 S L5
L7 10 S L5 AND (VIRUS OR VIRAL)

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	64.72	264.88
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-8.50	-8.50

STN INTERNATIONAL LOGOFF AT 12:45:30 ON 16 MAR 2010